BlinkLab Starts Pivotal FDA Validation for Digital Autism Diagnostic Aid

The latest announcement is out from Blinklab Limited ( (AU:BB1) ).

BlinkLab has commenced its pivotal FDA 510(k) validation program for its pediatric autism diagnostic aid BlinkLab Dx1, enrolling and completing testing of the first child participant in a study led by contract research organisation IQVIA-MCRA. The multi-centre, double-blinded U.S. trial, which follows a pilot study showing sensitivity of 83.7% and specificity of 84.7%, will assess usability and diagnostic performance against gold-standard clinical assessments, with recruitment expected to finish in about eight months and a regulatory submission targeted by late 2026.

The registrational study is being conducted across 10 leading U.S. autism research centres including Cincinnati Children’s Hospital, Seattle Children’s Hospital, the University of Pennsylvania and Vanderbilt Kennedy Center, providing a geographically and demographically representative sample. Successful completion of this program would generate the pivotal clinical and usability evidence needed for FDA review, potentially strengthening BlinkLab’s position in the emerging digital autism diagnostics market and improving access to earlier, technology-enabled autism assessment for children and their caregivers.

More about Blinklab Limited

BlinkLab Limited is an ASX-listed medtech company developing digital diagnostic aids for pediatric autism. Its core product, BlinkLab Dx1, uses objective digital biomarkers derived from patient behaviour to support clinicians in delivering earlier, more accurate and scalable autism assessments, with a key strategic focus on the U.S. regulatory and clinical market.

Average Trading Volume: 204,137

Technical Sentiment Signal: Buy

Current Market Cap: A$104.5M

For detailed information about BB1 stock, go to TipRanks’ Stock Analysis page.